TWO SIGMA INVESTMENTS, LP - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 136 filers reported holding REVANCE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.72 and the average weighting 0.5%.

Quarter-by-quarter ownership
TWO SIGMA INVESTMENTS, LP ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$20,674,195
-53.3%
816,839
-40.6%
0.05%
-59.1%
Q1 2023$44,267,427
+77.5%
1,374,338
+1.7%
0.13%
+62.8%
Q4 2022$24,942,303
-17.7%
1,351,154
+20.4%
0.08%
-24.3%
Q3 2022$30,289,000
+535.8%
1,121,823
+225.5%
0.10%
+543.8%
Q2 2022$4,764,000
+123.3%
344,688
+215.1%
0.02%
+166.7%
Q1 2022$2,133,000
+47.2%
109,396
+23.2%
0.01%
+100.0%
Q4 2021$1,449,000
+76.1%
88,806
+171.4%
0.00%0.0%
Q3 2020$823,000
+157.2%
32,722
+149.6%
0.00%
+50.0%
Q2 2020$320,000
-83.1%
13,109
-89.8%
0.00%
-86.7%
Q1 2020$1,894,000
+124.9%
127,967
+146.6%
0.02%
+400.0%
Q4 2019$842,000
+79.1%
51,902
+43.2%
0.00%
+50.0%
Q2 2019$470,000
-74.5%
36,242
-69.0%
0.00%
-66.7%
Q1 2019$1,844,000
+90.1%
117,012
+199.7%
0.01%
+100.0%
Q3 2018$970,000
-75.7%
39,039
-73.2%
0.00%
-75.0%
Q2 2018$3,999,000
+171.3%
145,677
+204.4%
0.01%
+140.0%
Q1 2018$1,474,000
-51.0%
47,855
-43.1%
0.01%
-50.0%
Q4 2017$3,008,000
+82.9%
84,142
+74.8%
0.01%
+25.0%
Q4 2015$1,645,000
+53.6%
48,146
-6.8%
0.01%
+60.0%
Q1 2015$1,071,00051,6730.01%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
Palo Alto Investors LP 4,405,039$118,936,0009.40%
Essex Woodlands Management, Inc. 457,085$12,341,0005.10%
Evolutionary Tree Capital Management, LLC 191,868$5,180,0004.98%
Ghost Tree Capital, LLC 390,000$10,530,0002.96%
Antara Capital LP 4,069,400$109,874,0002.90%
RICE HALL JAMES & ASSOCIATES, LLC 896,754$24,212,0001.40%
Jericho Capital Asset Management L.P. 714,000$19,278,0001.22%
Antara Capital LP 1,600,000$43,200,0001.14%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 120,000$3,240,0001.04%
TANG CAPITAL MANAGEMENT LLC 287,500$7,763,0000.95%
View complete list of REVANCE THERAPEUTICS INC shareholders